Oncothyreon: Clinical Trial Update (Oncothyreon) - Jul 18, 2015 - “ONT-10 has been well tolerated at doses through 1000 μg administered Q2W or QW over an 8-week period and when administered every 6 weeks as maintenance therapy for up to 11 months”; “Consistent with preclinical data, ONT-10 induces IgM and IgG anti-MUC1 response in the majority of patients, with titers frequently exceeding 1: 50,000”; “The data support a schedule and dose response, with the greatest IgG response to date occurring at the highest weekly dose tested, 1000 μg QW”; “T cell response analysis is ongoing. Preliminary evidence of induction of a T cell response has been seen using CD28/CD49d-costimulation in the ELISPOT assay”; “Encouraging disease control has been seen in patients with heavily pretreated and incurable cancers, and greater than 50% of patients have enrolled in the maintenance study”
P1 data • Oncology
|